1. Home
  2. STRS vs CHRS Comparison

STRS vs CHRS Comparison

Compare STRS & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stratus Properties Inc.

STRS

Stratus Properties Inc.

HOLD

Current Price

$19.70

Market Cap

220.4M

Sector

Real Estate

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.42

Market Cap

209.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRS
CHRS
Founded
1992
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
220.4M
209.8M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
STRS
CHRS
Price
$19.70
$1.42
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.51
AVG Volume (30 Days)
102.9K
700.5K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
512.50
472.00
EPS
0.82
N/A
Revenue
$29,914,000.00
N/A
Revenue This Year
N/A
$73.08
Revenue Next Year
N/A
$30.94
P/E Ratio
$23.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.53
$0.81
52 Week High
$32.93
$2.62

Technical Indicators

Market Signals
Indicator
STRS
CHRS
Relative Strength Index (RSI) 16.48 45.98
Support Level $18.51 $1.38
Resistance Level $20.57 $1.74
Average True Range (ATR) 0.74 0.06
MACD 0.01 0.00
Stochastic Oscillator 24.02 47.63

Price Performance

Historical Comparison
STRS
CHRS

About STRS Stratus Properties Inc.

Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the entitlement, development, management, leasing, and sale of multi-family and single-family residential and commercial real estate properties in the Austin, Texas area and other select markets in Texas. The company operates in two reportable segments: Real Estate Operations and Leasing Operations. Maximum revenue is generated from the Leasing Operations segment, which involves the leasing of commercial and residential properties developed by the company. The Real Estate Operations segment comprises properties under various stages of development: developed for sale, under development, and available for development.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: